In vitro experiments with triple negative breast cancer cells (MDA-MB-231) demonstrated that cells expressing the FGFR4 Arg388 variant have increased motility compared with cells expressing the FGFR4 wide-type counterpart (Gly388) [18]. The gene discussed is FGFR4; the disease is triple-negative breast carcinoma.